Literature DB >> 32600622

Geographic location of buprenorphine-waivered physicians and integration with health systems.

Brendan Saloner1, LeeKai Lin2, Kosali Simon3.   

Abstract

Efforts are underway to expand buprenorphine treatment for opioid use disorder (OUD) in hospitals and affiliated health systems, yet we do not know whether physicians who prescribe buprenorphine are likely to be health-system affiliated. Our study draws upon SK&A data covering primary care physicians and psychiatrists in eight states (California, Florida, Georgia, Maryland, Ohio, Rhode Island, Wisconsin, and West Virginia), which were linked to a list of waivered buprenorphine prescribers from the U.S. Drug Enforcement Agency. We calculated waivered rates stratified by patient limits, physician type, health system affiliation, and area-level characteristics. We mapped the spatial relationship between hospitals and waivered physicians in four metro areas. We found that primary care physicians affiliated with hospital health systems were less likely to have waivers than unaffiliated physicians (3.6% versus 8.2%), but the reverse was true for psychiatrists (33.2% versus 26.2%). Waivered physicians affiliated with health systems were less likely to practice in high-poverty areas than unaffiliated counterparts, and affiliated physicians were also more likely to cluster near hospitals. Health systems may be able to improve access to buprenorphine treatment in their communities by creating either incentives or mandates for more affiliated physicians to obtain a waiver.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Hospitals; Opioid use disorder; Primary care; Psychiatry

Mesh:

Substances:

Year:  2020        PMID: 32600622      PMCID: PMC7327133          DOI: 10.1016/j.jsat.2020.108034

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  21 in total

1.  Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.

Authors:  Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin
Journal:  J Gen Intern Med       Date:  2017-02-13       Impact factor: 5.128

2.  Attitudes, practices, and preparedness to care for patients with substance use disorder: Results from a survey of general internists.

Authors:  Sarah E Wakeman; Genevieve Pham-Kanter; Karen Donelan
Journal:  Subst Abus       Date:  2016 Oct-Dec       Impact factor: 3.716

3.  Medication-Based Treatment to Address Opioid Use Disorder.

Authors:  Alan I Leshner; Victor J Dzau
Journal:  JAMA       Date:  2019-06-04       Impact factor: 56.272

4.  Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Authors:  Roger A Rosenblatt; C Holly A Andrilla; Mary Catlin; Eric H Larson
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

5.  The Growing Integration of Physician Practices: With a Medicaid Side Effect.

Authors:  Michael R Richards; Sayeh S Nikpay; John A Graves
Journal:  Med Care       Date:  2016-07       Impact factor: 2.983

6.  Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose: A Cohort Study.

Authors:  Marc R Larochelle; Jane M Liebschutz; Fang Zhang; Dennis Ross-Degnan; J Frank Wharam
Journal:  Ann Intern Med       Date:  2015-12-29       Impact factor: 25.391

7.  Market environment and Medicaid acceptance: What influences the access gap?

Authors:  Amelia Bond; William Pajerowski; Daniel Polsky; Michael R Richards
Journal:  Health Econ       Date:  2017-03-28       Impact factor: 3.046

8.  Trends in hospital ownership of physician practices and the effect on processes to improve quality.

Authors:  Tara F Bishop; Stephen M Shortell; Patricia P Ramsay; Kennon R Copeland; Lawrence P Casalino
Journal:  Am J Manag Care       Date:  2016-03       Impact factor: 2.229

9.  Leveraging Diverse Data Sources to Identify and Describe U.S. Health Care Delivery Systems.

Authors:  Genna R Cohen; David J Jones; Jessica Heeringa; Kirsten Barrett; Michael F Furukawa; Dan Miller; Anne Mutti; James D Reschovsky; Rachel Machta; Stephen M Shortell; Taressa Fraze; Eugene Rich
Journal:  EGEMS (Wash DC)       Date:  2017-12-15

10.  "Maybe if I stop the drugs, then maybe they'd care?"-hospital care experiences of people who use drugs.

Authors:  Soo Chan Carusone; Adrian Guta; Samantha Robinson; Darrell H Tan; Curtis Cooper; Bill O'Leary; Karen de Prinse; Grant Cobb; Ross Upshur; Carol Strike
Journal:  Harm Reduct J       Date:  2019-02-13
View more
  5 in total

1.  Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.

Authors:  Mark Katz Meiselbach; Coleman Drake; Brendan Saloner; Jane M Zhu; Bradley D Stein; Daniel Polsky
Journal:  Health Aff (Millwood)       Date:  2022-06       Impact factor: 9.048

2.  Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study.

Authors:  Joshua A Barocas; Alexandra Savinkina; Joella Adams; Raagini Jawa; Zoe M Weinstein; Jeffrey H Samet; Benjamin P Linas
Journal:  Lancet Public Health       Date:  2021-11-30

3.  Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.

Authors:  Pia M Mauro; Sarah Gutkind; Erin M Annunziato; Hillary Samples
Journal:  JAMA Netw Open       Date:  2022-03-01

4.  It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Authors:  Brendan Saloner; Barbara Andraka Christou; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2021-04-02       Impact factor: 3.716

5.  A Resident-Led Intervention to Increase Initiation of Buprenorphine Maintenance for Hospitalized Patients With Opioid Use Disorder.

Authors:  Ashish P Thakrar; David Furfaro; Sara Keller; Ryan Graddy; Megan Buresh; Leonard Feldman
Journal:  J Hosp Med       Date:  2021-06       Impact factor: 2.899

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.